United States Cell and Gene Therapy Manufacturing QC Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, CAR-T, CAR-NK, B-Cell, Others, Gene Therapy, Viral, Non-viral), By Scale (Pre-commercial/ R&D Manufacturing, Commercial Scale Manufacturing), By Mode (Contract Manufacturing, In-house Manufacturing), By Workflow (Cell Processing, Cell Banking, Fill & Finish Operations, Raw Material Testing, Vector Production, Other Workflows), By Process (Upstream Processes, Downstream Processes), By End-User (Pharmaceutical Companies, Biopharmaceutical / Biotechnological Companies, Contract Manufacturing Organizations), By Technology Type (Fluorescence-Activated Cell Sorting (FACS), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Others) and Forecasts, 2025-2033

United States Cell and Gene Therapy Manufacturing QC Market Size

The United States cell and gene therapy manufacturing QC market size was valued at USD 792.10 million in 2024 and is estimated to reach from USD 994.08 million in 2025 to USD 6,117.49 million by 2033, growing at a CAGR of 25.5% during the forecast period (2025–2033).

This market is experiencing rapid growth, driven by the surging efforts of key players to technologically advance these QC solutions. In addition, there has also been a rise in the government and public initiatives supporting research and development in this field, thereby creating opportunities for market growth.

United States Cell and Gene Therapy Manufacturing QC Market Growth Drivers

Technological advancements in qc tools

Technological advancements in QC tools are a major growth driver for the U.S. cell and gene therapy manufacturing QC market. The integration of automated systems, next-generation sequencing (NGS), and real-time polymerase chain reaction (PCR) technologies has revolutionized the quality assessment of gene-modified cells. These tools allow for precise characterization of vector genomes, tracking of genetic modifications, and identification of potential contaminants.

Companies like Thermo Fisher Scientific and Bio-Rad Laboratories are spearheading innovations in real-time monitoring systems that improve the accuracy and speed of QC processes. As the industry moves toward automation and digital solutions, these technological advancements are expected to lower costs and increase the scalability of QC operations.

Market Restraint

Shortage of skilled personnel

One significant restraint is the shortage of highly skilled professionals required for cell and gene therapy QC. The complexity of these therapies demands expertise in fields like molecular biology, bioinformatics, and advanced QC technologies. However, the industry faces a talent gap, with few professionals adequately trained in handling the sophisticated QC processes involved in gene editing, viral vector analysis, and cell characterization.

This shortage has increased the operational costs for companies that need to invest in training programs or hire top-tier talent at higher salaries. According to a 2022 report by the Biotechnology Innovation Organization (BIO), nearly 65% of biotech companies in the U.S. reported difficulties in finding qualified staff for advanced therapeutic production, which includes QC activities. This talent gap slows down QC operations and limits the scalability of manufacturing processes.

Market Opportunities

Government funding and public-private partnerships

The increasing government interest in regenerative medicine and advanced therapeutics is opening up opportunities for public-private partnerships and funding initiatives aimed at improving QC standards. In the U.S., the National Institutes of Health (NIH) and other government bodies have started offering grants and support for projects that enhance the safety and scalability of cell and gene therapies.

• For instance, the NIH's Regenerative Medicine Innovation Project has provided funding to various research initiatives aimed at improving the production and quality control of these therapies. Moreover, partnerships between academic institutions, government agencies, and private companies are facilitating the development of new QC techniques and frameworks that meet regulatory standards while accelerating production timelines.

These initiatives are expected to drive advancements in the QC market, making it easier for manufacturers to meet compliance requirements without significantly increasing costs.

Regional Analysis

The U.S. is a global leader in cell and gene therapy research and development, making it the largest market. The Northeast U.S. is home to major biotech hubs, particularly in Massachusetts (Boston-Cambridge area) and New Jersey, which are pivotal in the cell and gene therapy space. According to the Massachusetts Biotechnology Council, Massachusetts alone has more than 1,000 biopharmaceutical companies involved in advanced therapies, accounting for 20% of the global pipeline for gene therapies.

Additionally, California is another key region, with numerous firms focused on gene therapy development. The San Francisco Bay Area and San Diego are major biotech hubs in California, with companies like Sangamo Therapeutics and Audentes Therapeutics leading gene therapy development. California's gene therapy sector has seen a 33% increase in investment between 2018 and 2022, driven by VC funding and collaborations with academic institutions. The state's focus on innovation and R&D is positioning California as a leading region for QC technology adoption.

Furthermore, while traditionally known for pharmaceutical manufacturing, regions like Texas (Houston) and North Carolina (Research Triangle Park) are emerging as key players in the market. North Carolina's Research Triangle Park has attracted 20+ gene therapy companies, including AveXis and Precision BioSciences, due to the state's competitive operating costs and workforce availability.

Texas, particularly Houston, is becoming a prominent region due to institutions like MD Anderson Cancer Center, which has collaborated on CAR-T therapies and is driving clinical trial growth in cell therapy. This expansion is expected to increase the demand for local QC testing facilities to ensure compliance with federal and state regulations.

Consequently, the factors above are estimated to drive market growth in the U.S.

Segmental Analysis

The US cell and gene therapy manufacturing QC market is segmented by therapy type, scale, mode, workflow, process, end-user, and technology type.

By process

Upstream Processes dominates the process segment and is estimated to grow at a CAGR of 25.3%. The upstream processes segment in the U.S. cell and gene therapy manufacturing QC market is witnessing significant growth due to increasing demand for robust cell expansion and viral vector production. These processes are crucial for scaling up therapeutic manufacturing and ensuring high-quality yields for both clinical and commercial applications.

By end user

Biopharmaceutical/biotechnological companies are estimated to own the end-user segment and are anticipated to expand at a CAGR of 25.2%. Biopharmaceutical and biotechnological companies are driving the market's growth due to their heavy investments in cell and gene therapy development. These companies focus on in-house QC processes to meet regulatory requirements, ensuring the safe production of advanced therapies and accelerating commercialization in this growing therapeutic field.

By technology type

Polymerase Chain Reaction (PCR) dominates the technology type segment and is expected to augment at a CAGR of 26.0%. The Polymerase Chain Reaction (PCR) technology segment is expanding due to its precision and effectiveness in detecting genetic modifications and viral vectors in these therapies. PCR's high sensitivity and rapid results make it an essential QC tool, particularly in ensuring the safety and efficacy of cell and gene-based products.

Analyst's Perspective

As per our research analysts, the future of the United States cell and gene therapy manufacturing QC market is vibrant, underpinned by technological innovation, increasing regulatory demand, and infrastructure investments. Companies that can provide scalable, compliant, and technologically advanced QC solutions will find a wealth of opportunities as the market grows in tandem with the cell and gene therapy industry. In the future, we expect to see QC processes become more integrated into manufacturing workflows, reducing costs, ensuring higher quality, and ultimately accelerating patient access to life-saving therapies.